Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Accelerated approval

Qualitative segmentation validation study with backroom brainstorm exercises

Our client had an oncology product in development for the treatment of prostate cancer. The company wanted to conduct research to inform future planning, list development, advisory board creation, and...

Research Partnership

Perspective on biotech

In this supplementary issue of Perspective, we reveal the emerging technologies taking the biotech world by storm and ask if the definition of a biotech organisation needs updating.

Blue Latitude Health

- PMLiVE

GSK’s pipeline cull claims sirukumab, and possibly rare disease unit

Makeover designed to deliver a leaner, fitter company in 2020

Immunotherapies in oncology: the future of cancer treatment lies in combinations and partnerships

Anne Legendre reviews the scientific rationale behind immunotherapy combinations and Frances Hendry examines how partnerships, co-marketing and positioning drugs will play key roles in shaping the competitive landscape in oncology.

Blue Latitude Health

Therapy Watch expands oncology and IBD portfolios

This month Therapy Watch expands its portfolio with the launch of several new trackers across numerous therapy areas including the launch of a new Chronic Myelogenous Leukaemia (CML) study in...

Research Partnership

Using service design to improve patients’ quality of life

Customer Experience Consultant Eimear Power talks through the process of developing Orello, a service for metastatic prostate cancer patients and their loved ones, in collaboration with Janssen.

Blue Latitude Health

- PMLiVE

Caring for prostate cancer patients

Although not without its challenges, the appropriate care and support available to patients with prostate cancer is gradually evolving. It’s important not to overlook the all too often ‘unsung heroes’...

Blue Latitude Health

- PMLiVE

Novartis’ Zykadia nears first-line lung cancer label

Hopes to boost slow second-line sales to compete directly with Pfizer’s Xalkori and Roche’s Alecensa 

- PMLiVE

Argos hit as kidney cancer immunotherapy fails phase III trial

Study discontinued as data shows renal cell carcinoma vaccine unlikely to meet targets

AstraZeneca AZ

AZ agrees to $320m deal for Zoladex

TerSera Therapeutics acquires rights to oncology drug in US and Canada

- PMLiVE

New guide to improve cancer control published in EU

Outlines recommendations to boost quality of life and reduce financial burden

- PMLiVE

Winning the war against cancer

Dr Josep Figueras on survival, access to treatments and the need for good data in oncology

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links